[A study comparing 131I versus 131I plus antithyroid drug in the management of Graves' disease].
OBJECTIVE
To ascertain whether the therapoutic effect of 131I is affected by the additional use of thyrostatic medication.


METHODS
One hundred and eighty-seven patients with Graves' disease (GD) were randomly assigned to treatment with 131I alone or plus thyrostatic medication(PTU) 3 days after the beginning of 131I therapy. All patients were examined every month for six months after treatment.


RESULTS
The cure of hyperthyroidism occurred in 71 of 93 patients(76.3%) treated with 131I alone and in 76 of 94 patients(80.5%) treated with 131I plus thyrostatic medication(PTU). There were no significant differences in cure rate between the two groups.


CONCLUSIONS
The additional use of thyrostatic medication 3 days after the beginning of 131I therapy will not affect the efficacy of 131I in the treatment of GD.
Tian
R
R
Department of Nuclear Medicine, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
Kuang
A
A
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011441:Propylthiouracil / Q000627:therapeutic use*
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D011441:Propylthiouracil